What is PLUR's market cap?

$16.09M, based on the Nov 5 close of $1.19.

Does Pluri pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PLUR is sold short?

21.0K shares, 0.3% of float, as of Oct 15, 2026.

What sector is PLUR in?

Healthcare, in the Biotechnology industry.

NASDAQ · PLURHealthcareBiotechnology

Pluri Inc. Common Stock (PLUR)

$1.19−3.26%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$1.21▼ 65.82% in range

Nov 4, 2025Low $0.85 · High $4.45Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

Pluri closed at $1.19 on Nov 5, down 3.26%, 73.3% below its 52-week closing high. Volume of 27.6K shares was 0.43× its 20-day average (below normal).

Split-adjusted performance: +14.4% over one month, -64.4% over six months.

In the quarter ended Jun 30, 2026, revenue was $335K, down 15.8% from a year earlier, with a net margin of -1755.2%.

Short interest was 21.0K shares at the Oct 15 settlement, up 8.9% from the prior report (0.3% of float, 1.8 days to cover).

Market cap$16.1M13.5M shares

Revenue · quarter$335.0K−15.8% YoY

Diluted EPS$-0.55—

P/E · TTM—P/S 15.8×

Net margin-1,755.2%Gross 58.5%

Dividend yieldNone

52-week range0.85 – 4.45−73.3% from high

Volume27.6K0.43× 20-day avg

Volatility · 60d80.2%Annualised

Short % of float0.3%1.8 days to cover

Net cash-$23.9MCash $3.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −0.8%1M +14.4%3M −34.6%6M −64.4%YTD −60.2%1Y —3Y −70.6%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum16

Revenue growth34

Net margin22

Value (low P/E)—

Size15

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →

Shares short21.0K+8.9% vs prior

Days to cover1.8Settled Oct 15

% of float0.3%

Short vol. 10d42.4%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PLURPluri	$1.19	−3.26%	−64.4%	−15.8%	−1755.2%	—	$16.1M
JSPRJasper Therapeutics	$0.4692	−8.20%	−48.3%	—	—	—	$15.6M	Compare
ABOSAcumen Pharmaceuticals	$0.2138	−1.16%	−91.3%	—	—	—	$15.5M	Compare
ATYRaTyr Pharma	$6.03	−2.43%	−83.6%	—	—	—	$15.1M	Compare
ESLAEstrella Immunopharma	$0.4101	−7.53%	−67.7%	—	—	—	$17.8M	Compare
BKHABlack Hawk Acquisition	$4.50	−19.21%	—	—	—	—	$18.7M	Compare
DYAIDyadic International	$0.3401	−7.25%	−54.3%	−0.6%	−221.0%	—	$13.6M	Compare
BCDABioCardia	$0.8900	−2.53%	−18.3%	—	—	—	$13.5M	Compare
BSEMBioStem Technologies	$1.04	−9.57%	—	—	—	—	$19.4M	Compare

News about Pluri

All news →

No recent articles focused on Pluri.

Quick answers

What does Pluri do?: Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions.
What is PLUR's market cap?: $16.09M, based on the Nov 5 close of $1.19.
Does Pluri pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PLUR is sold short?: 21.0K shares, 0.3% of float, as of Oct 15, 2026.
What sector is PLUR in?: Healthcare, in the Biotechnology industry.

About Pluri

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

HQ: Haifa, 113 employeesListed Oct 9, 1991pluri-biotech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology